Association of PIK3CA mutations with efficacy in HER2-positive first-line metastatic breast cancer: a meta-analysis

被引：0
|
作者：
Swain, Sandra
Cortes, Javier
Xu, Binghe
Lambertini, Chiara
Essioux, Laurent
Knott, Adam
Restuccia, Eleonora
Madjar, Katrin
De Haas, Sanne Lysbet
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-11-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-11-07
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
    Goel, S.
    Krop, I. E.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (08) : 1368 - 1372
  • [2] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis
    Feng, Fubin
    Zhang, Tingting
    Yin, Fang
    Liu, Cun
    Zhuang, Jing
    Qi, Lingyu
    Wang, Xue
    Li, Jia
    Wang, Lu
    Tian, Jinhui
    Sun, Changgang
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 959 - 974
  • [4] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    Cizkova, M.
    Dujaric, M-E
    Lehmann-Che, J.
    Scott, V.
    Tembo, O.
    Asselain, B.
    Pierga, J-Y
    Marty, M.
    de Cremoux, P.
    Spyratos, F.
    Bieche, I.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1807 - 1809
  • [5] Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis
    Leung, Henry W. C.
    Leung, John-Hang
    Chan, Agnes L. F.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (01) : 1 - 7
  • [6] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    [J]. British Journal of Cancer, 2013, 108 : 1807 - 1809
  • [7] Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis
    Shi, Qiyun
    Xuhong, Juncheng
    Tian, Hao
    Qu, Man
    Zhang, Yi
    Jiang, Jun
    Qi, Xiaowei
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (01):
  • [8] Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer: A Bayesian network meta-analysis
    Li, Lixi
    Wu, Yun
    Lan, Bo
    Ma, Fei
    [J]. CANCER INNOVATION, 2024, 3 (04):
  • [9] PertuzumabIn the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Gillian M. Keating
    [J]. Drugs, 2012, 72 : 353 - 360
  • [10] Pertuzumab In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Keating, Gillian M.
    [J]. DRUGS, 2012, 72 (03) : 353 - 360
12345